Health atroposA company that translates clinical data from the real world (RWD) in real evidence, announced a strategic partnership with Ontada, a McKesson Business involved in community oncology.
Ontada is connected to US Oncology Network, a subsidiary in exclusive McKesson, which provides real -time data, ideas and research on how cancer is treated in a community.
Collaboration aims to strengthen use cases for clinicians, researchers and health leaders to design care protocols, promote precision medicine and create new treatments in oncology.
Automation tools of atropos Health produce evidence from a client’s data by installing Geneva OS, its operating system for rapid health care evidence, in the client cloud data environment and the network of atropos evidence.
The members of the evidence network can take advantage of the longitudinal data of patients from participating network sources, which gives them access to disidentified patient files while preserving the possession and the security of the data.
Members can also run requests on the RWD in the atropos evidence network and access data for each question that the real fitness score assesses.
The collaboration follows the announcement in March of Atropos Health of federated nodal disidentification technology, which will be added to the Geneva platform and accessible to members of the Atropos evidence network.
According to the company, nodal disidentification allows users to fill the data gaps in longitudinal files of patients from participating atropos network sources.
“High -quality data demand in oncology is still present,” said Brigham Hyde, CEO and co -founder of Atropos Health, in a press release.
“The network of atropos evidence, which will now include Ontada RWD, includes advantages throughout the health care ecosystem. For health systems, the multimodal network in oncology contains high quality RWD necessary to generate the RWE necessary for clinical decisions with high issues.”
The biggest trend
In February, EMORY Healthcare In partnership with the Atropos Health To Advance form Decisions and Protocols. EMORY has piloted a program to advance patient care by allowing clinical questions to answer in real time using the atropos platform.
The network of atropos evidence allows EMORY users to carry out studies on national data sets and local EMORY data. Clinicians also use the green button of atropos to access RWE.
In January, Atropos Health joined forces with xcuresA data recovery company on health care fueled by AI, to operate information based on RWE in Support patient care.
The partnership aimed to take advantage of AI, the atropos evidence network and the Xcures platform to develop and deploy prognostic and decision-making tools approved to health care providers in the health care ecosystem.
This same month, Atropos has teamed up with Cripple to generate RweReflection studies and produce rapid information and analyzes on real world data.
Merck and RWE data science teams will use Atropos Health Services, including Geneva OS Green Button, the Atropos and Alexandria, Forge and Chatrwd evidence network.
In 2024, the atropos secured 33 million dollars in series B financing.
Valtruis directed the investment tour, which included new investors Ventures McKesson,, Merck GHI funds and Cencora Ventures.
Existing investors Collective Emerson,, Breyer Capital and Presidio Ventures also participated in the round
Mike Spadafore, Managing Director of Valtruis, joined the company’s board of directors.
Atropos also announced that the health data analysis company Arcadia joins her health wallet That year, giving customers of Arcadia suppliers and users of life sciences to access atropos offers.
Via the partnership, Arcadia joined the atropos evidence network, which gave its users access to the atropos applications portfolio to support clinical decision -making in value -based care.